Abstract
Our objective was to determine the optimal approach for assessing amyloid disease in a cognitively normal elderly population. Methods: Dynamic 18F-flutemetamol PET scans were acquired using a coffee-break protocol (a 0- to 30-min scan and a 90- to 110-min scan) on 190 cognitively normal elderly individuals (mean age, 70.4 y; 60% female). Parametric images were generated from SUV ratio (SUVr) and nondisplaceable binding potential (BPND) methods, with cerebellar gray matter as a reference region, and were visually assessed by 3 trained readers. Interreader agreement was calculated using κ-statistics, and semiquantitative values were obtained. Global cutoffs were calculated for both SUVr and BPND using a receiver-operating-characteristic analysis and the Youden index. Visual assessment was related to semiquantitative classifications. Results: Interreader agreement in visual assessment was moderate for SUVr (κ = 0.57) and good for BPND images (κ = 0.77). There was discordance between readers for 35 cases (18%) using SUVr and for 15 cases (8%) using BPND, with 9 overlapping cases. For the total cohort, the mean (±SD) SUVr and BPND were 1.33 (±0.21) and 0.16 (±0.12), respectively. Most of the 35 cases (91%) for which SUVr image assessment was discordant between readers were classified as negative based on semiquantitative measurements. Conclusion: The use of parametric BPND images for visual assessment of 18F-flutemetamol in a population with low amyloid burden improves interreader agreement. Implementing semiquantification in addition to visual assessment of SUVr images can reduce false-positive classification in this population.
Original language | English |
---|---|
Pages (from-to) | 541-547 |
Number of pages | 7 |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine |
Volume | 60 |
Issue number | 5 |
Early online date | 12 Oct 2018 |
DOIs | |
Publication status | Published - May 2019 |
Funding
This project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant 115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant 115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Support was also received from the NIHR UCLH Biomedical Research Center, and in-kind sponsoring of the PET tracer was received from GE Healthcare. Philip Scheltens received grants from GE Healthcare, Piramal, and Merck, paid to his institution, and speaker’s fees paid to the Alzheimer Center, VU University Medical Center, Lilly, GE Healthcare, and Roche. Pieter Jelle Visser received research support from Biogen and grants from EU/EFPIA IMI Joint Undertaking, EU Joint Programme–Neurodegenerative Disease Research (JPND), ZonMw, and Bristol-Myers Squibb; served as a member of the advisory board of Roche Diagnostics; and received nonfinancial support from GE Healthcare. Frederik Barkhof received payment and honoraria from Bayer-Schering Pharma, Sanofi-Aventis, Gen-zyme, Biogen-Idec, TEVA, Merck-Serono, Novartis, Roche, Jansen Research, IXICO Ltd., GeNeuro, and Apitope Ltd. for consulting; payment from the Serono Symposia Foundation, IXICO Ltd., and MedScape for educational presentations; and research support via grants from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020), U.K. MS Society, Dutch MS Society, PICTURE (IMDI-NWO), and ECTRIMS-MAGNIMS. No other potential conflict of interest relevant to this article was reported.
Funders | Funder number |
---|---|
Bayer-Schering Pharma | |
Biogen-Idec | |
Dutch MS Society | |
ECTRIMS-MAGNIMS | |
EU-EFPIA IMI-2 | |
EU/EFPIA | |
EU/EFPIA Innovative Medicines Initiative | |
EuroPOND | |
IMDI-NWO | |
Merck-Serono | |
Piramal | |
Serono Symposia Foundation | |
Bristol-Myers Squibb | |
Novartis | |
Roche | |
Sanofi | |
Biogen | |
Teva Pharmaceutical Industries | |
GE Healthcare | |
Horizon 2020 Framework Programme | |
Seventh Framework Programme | 115372, 115952 |
EU Joint Programme – Neurodegenerative Disease Research | |
European Federation of Pharmaceutical Industries and Associations | |
Multiple Sclerosis Society | |
ZonMw | |
Horizon 2020 | |
Innovative Medicines Initiative | |
IXICO |
Keywords
- 18F-flutemetamol PET
- amyloid pathology
- preclinical Alzheimer disease
- visual assessment